miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP.
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumor in Southeast Asia, its regulatory mechanism is still to be understood. miR-519 inhibits the progression of several tumors, including cervical cancer, ovarian cancer and gastric cancer. But its role in NPC hasn't been studied. In present study, we found miR-519 was downregulated in NPC cells, its overexpression inhibited NPC cell proliferation and arrested cell cycle at G0/G1 phase, while its knockdown promoted NPC cell proliferation and cell cycle progression. An oncogene URG4/URGCP (upregulated gene-4/upregulator of cell proliferation) was the target of miR-519, URG4 was upregulated in NPC cells, miR-519 inhibited URG4 expression by directly binding to the 3'UTR of URG4. miR-519 inhibited Cyclin D1 expression and the phosphorylation level of Rb, and increased p21 and p27 expression, confirming miR-519 blocked G1/S transition. Moreover, miR-519 level was negative correlated with URG4 level in NPC tissues. In summary, we found miR-519 NPC cell proliferation by inhibiting URG4.
ENT & HN Surgery Department, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China. Electronic address: entyu2015@163.com.
Guodong
G
Yu
ENT & HN Surgery Department, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Tian
T
Zhang
ENT & HN Surgery Department, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Ying
Y
Jing
ENT & HN Surgery Department, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Qingmin
Q
Bao
ENT & HN Surgery Department, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Qiang
Q
Tang
ENT & HN Surgery Department, Guizhou Cancer Hospital, Guiyang, Guizhou, China.
Yu
Y
Zhang
D002277:Carcinoma; D045744:Cell Line, Tumor; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics / Q000378:metabolism; D016193:G1 Phase; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis* / Q000235:genetics; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D012334:RNA, Neoplasm / Q000096:biosynthesis* / Q000235:genetics; D016160:Retinoblastoma Protein / Q000235:genetics / Q000378:metabolism; D016196:S Phase; D015854:Up-Regulation
C530104:CCND1 protein, human; C493956:CDKN1A protein, human; C436291:CDKN1B protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; C546194:MIRN519 microRNA, human; D035683:MicroRNAs; D009363:Neoplasm Proteins; D012334:RNA, Neoplasm; D016160:Retinoblastoma Protein; C470990:URGCP protein, human; D019938:Cyclin D1; D050760:Cyclin-Dependent Kinase Inhibitor p27
Nasopharyngeal carcinoma; Proliferation; URG4; miR-519